Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Conditions
Brief summary
This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.
Interventions
PROCEDUREBiopsy Procedure
Undergo tumor biopsy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREBone Marrow Aspiration
Undergo bone marrow aspiration
PROCEDUREBone Marrow Biopsy
Undergo bone marrow biopsy
BIOLOGICALCiltacabtagene Autoleucel
Given IV
PROCEDUREComputed Tomography
Undergo CT scan
DRUGCyclophosphamide
Given IV
DRUGDasatinib
Given PO
DRUGFludarabine
Given IV
PROCEDUREPositron Emission Tomography
Undergo PET scan
DRUGQuercetin
Given PO
Sponsors
Mayo Clinic
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Relapsed or refractory multiple myeloma who has had at least 3 prior lines of therapies including a proteasome inhibitor, immunomodulatory drug (IMiD) and anti-CD38 monoclonal antibody (mAb) * Ciltacabtagene autoleucel (Carvykti) available for patient * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Life expectancy ≥ 12 weeks * Hemoglobin ≥ 8.0 g/dL (obtained ≤ 14 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 14 days prior to registration) * Platelet count ≥ 50,000/mm\^3 (obtained ≤ 14 days prior to registration) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration) * Note: Patients with Gilbert's syndrome must have a total bilirubin of ≤ 3 x ULN (obtained ≤ 14 days prior to registration) * Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2 x ULN (obtained ≤ 14 days prior to registration) * Alkaline phosphatase ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration) * Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration) * Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only * Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry and for the duration of study participation and for at least 30 days after the last dose of study drug * Provide written informed consent * Willingness to provide mandatory blood and bone marrow specimens for correlative research * Willingness to provide mandatory bone marrow cores and/or tissue specimens for correlative research * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Exclusion criteria
* Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or AL amyloidosis * Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment. * EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 1 month since completion of prior treatment * Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects: * Pregnant persons * Nursing persons * Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception * Major surgery ≤ 28 days prior to registration * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Immunocompromised patients and patients known to be HIV positive. * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, or those currently receiving antiretroviral therapy with good control of HIV, are eligible for this trial * Evidence of cardiovascular disease risk, as defined by any of the following: * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening. * Class III or IV heart failure as defined by the New York Heart Association functional classification system * Uncontrolled hypertension * History of life-threatening ventricular arrhythmias * QTC interval \[electrocardiogram (ECG)\] ≥ 450 msec * Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Any medical condition that would make participation unduly hazardous * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Live vaccine ≤ 6 weeks prior to registration * Has taken a strong inhibitor or inducer of CYP3A4/5, including grapefruit, St. John's Wort or related products ≤ 14 days prior to registration. * Note: If required, patients may receive a short course of strong inhibitors or inducers for treatment of symptoms, but dasatinib dose must be adjusted as indicated * Known hypersensitivity or allergy to dasatinib or quercetin * Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc). * On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.) * NOTE: Baby aspirin, if necessary for cardioprotection, will be allowed * On quinolone antibiotic therapy for treatment or for prevention of infections products ≤10 days prior to registration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Minimal residual disease (MRD) negativity rate | At 3 months | Defined as the number of patients who are able to achieve undetectable MRD based on bone marrow (BM) and positron emission tomography (PET) evaluations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | Up to 2 years | Assessed by the number of patients who achieve any response (partial response or better) to therapy. |
| Depth of response | Up to 2 years | Assessed by the number of patients who are able to achieve different levels of response, such as partial response (PR), very good partial response (VGPR), and complete response (CR), or stringent complete response (sCR). |
| Progression free survival (PFS) | Up to 2 years | Defined as the time from study registration to the time of documented disease progression or death due to any cause. |
| Duration of response | Up to 2 years | Defined as the time from first documented response to the time of progression and/or death due to any cause. |
| Incidence of adverse events (AEs) | Up to 2 years | AEs will be summarized per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5, and where toxicities will be defined as adverse events that are deemed to be at least possibly treatment-related. The maximum grade for each type of treatment-related AE will be recorded for each patient, and the frequency of each will be summarized. |
Countries
United States
Contacts
CONTACTClinical Trials Referral Office
PRINCIPAL_INVESTIGATORYi Lin, MD, PhD
Mayo Clinic
Outcome results
None listed